Athenex, Inc. (NASDAQ:ATNX) headquartered in Buffalo, will host a conference call for the investment community to discuss the 3Q20 financial results on 5th November 2020 at 8:00 AM Eastern Time.
The conference call will also be webcast live under the investor relations section of the website www.athenex.com
Earnings Expectation
Athenex, Inc. clinical stage biopharmaceutical firm, is reporting third quarter earnings results on Thursday 5th November 2020, before market open.
The consensus estimates from Thomson Reuters are loss of $ 0.43 per share from $ 23.11 million in revenue. For the full year, analysts predict revenues of $ 131.11 million, while looking forward to loss of $ 1.63 per share.
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. It operates in three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The companys Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer.
